Compare Packaging Corporation of America (PKG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Packaging Corporation of America vs TG Therapeutics Inc — how do they compare? Packaging Corporation of America trades at $228.27 (market cap $20.33B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Packaging Corporation of America is far larger — about 2.5× TG Therapeutics Inc's market cap, and Packaging Corporation of America pays a 2.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PKG | TGTX | |
|---|---|---|
Market Cap | $20.33B | $8.26B |
Sector | Technology | Health |
52-Week High | $246.31 | $59.06 |
52-Week Low | $191.41 | $26.39 |
Enterprise Value | $24.16B | $8.50B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Packaging Corp of America (PKG) trades at $228.43, down 1.99% on the day, with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $8.99B revenue and 8.04% net margin, though recent earnings show mixed performance with Q1 2026 beating estimates but Q3/Q4 2025 missing. A 20% dividend increase to $6.00 annually reflects management confidence. Analyst consensus is mixed with 34.62% buy ratings and a $256.14 price target suggesting 12% upside potential.
PKG presents a balanced investment case with attractive dividend yield and analyst upside, but faces earnings volatility and margin pressure. The upcoming Q2 2026 earnings report on July 22 will be crucial for confirming growth trajectory. Key risks include integration challenges from the Greif acquisition and ongoing cost pressures affecting profitability.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
